Threshold jumps on TH-302 data

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) gained $1.48 (42%) to $5.01 on Tuesday after TH-302 plus gemcitabine met the primary endpoint of median progression-free survival (PFS) vs. gemcitabine alone in a Phase IIb trial to treat advanced pancreatic cancer (5.6 vs. 3.6 months, p=0.005). Additionally, TH-302 plus gemcitabine led to a greater response rate compared to gemcitabine alone (22% vs. 12%). The open-label, crossover, U.S. trial enrolled 214 previously untreated patients. ...